Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 41 min ago
Peer-reviewedCC BYCurrent treatment options in oncology

Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease.

  • Ryan D Watkins1
  • Lee D Cranmer2
  • Sagus Sampath3
  • Adam G Rock2
  • Bridget N Fahy1
  • William W Tseng4
4 affiliations
  1. 1Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, 91010, USA.
  2. 2Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, USA.
  3. 3Department of Radiation Oncology, City of Hope National Medical Center, Duarte, USA.
  4. 4Department of Surgery, Division of Surgical Oncology, City of Hope National Medical Center, Duarte, 91010, USA. [email protected].
Read full textPDFDOICite

Abstract

Opinion statement

Retroperitoneal sarcomas are a group of rare malignancies comprised of several histological types, each carrying a unique risk of local recurrence and metastatic potential. In primary disease, surgery remains the mainstay of treatment and is the best opportunity for cure. In recurrent disease, treatment algorithms are less well defined. Surgery, radiation, systemic therapy, and in select cases, observation can be considered for management of recurrent disease. Histologic type drives a significant portion of clinical decision-making but incorporating all relevant clinicopathological data is important. To guide selection and timing of treatment, patients should undergo risk stratification. Nomograms and risk calculators are available to facilitate this. Experience and clinical judgement remain paramount. In the future, deeper molecular and radiologic characterization may further optimize decision-making in these challenging cases.

Related

  1. Real-World Management and Survival Outcomes in Patients with Primary or Recurrent Retroperitoneal Liposarcoma: A Single-Center Retrospective Cohort Study
    Atsuhiro Kijima, Nobuki Furubayashi, Takahito Negishi +1
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  2. Case Report: Recurrent retroperitoneal dedifferentiated liposarcoma after surgery
    Deng Hu, Yao-dong Wang, Shi-chun Jiang +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  3. MetALD in Clinical Practice: Diagnosis, Non-Invasive Risk Stratification, and Management
    Hubert Krzewiński, Oliwier Wątroba, Jarosław Koza
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Metaplasia intestinal gástrica: actualización en epidemiología, diagnóstico, estratificación del riesgo y manejo clínico Gastric Intestinal Metaplasia: an Update on Epidemiology, Diagnosis, Risk Stratification, and Clinical Management
    Luis Capella-Vernia, Irina Luzko, Leticia Moreira
    Acta gastroenterologica LatinoamericanaPeer-reviewedCC BY-NC-SAFull textGeneral medicineEurope PMC
  5. CD20-Positive B-Cell Non-Hodgkin Lymphoma Associated With Recurrent Acute Pancreatitis, Bilateral Renal Lesions, and Retroperitoneal Lymphadenopathy.
    Rehan Sarfraz, Magnie L Ledesma Leon, Dunia Nabi +2
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{watkins2026clinical,
  title = {{Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease.}},
  author = {Ryan D Watkins and Lee D Cranmer and Sagus Sampath and Adam G Rock and Bridget N Fahy and William W Tseng},
  journal = {Current treatment options in oncology},
  year = {2026},
  month = nov,
  doi = {10.1007/s11864-026-01418-9},
  url = {https://europepmc.org/article/MED/42972156},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Clinical Management and Risk Stratification of Retroperitoneal Sarcoma with a Focus on Locally Recurrent Disease.
AU  - Ryan D Watkins
AU  - Lee D Cranmer
AU  - Sagus Sampath
AU  - Adam G Rock
AU  - Bridget N Fahy
AU  - William W Tseng
PY  - 2026
DA  - 2026/11/03
JO  - Current treatment options in oncology
DO  - 10.1007/s11864-026-01418-9
UR  - https://europepmc.org/article/MED/42972156
AB  - Opinion statement  Retroperitoneal sarcomas are a group of rare malignancies comprised of several histological types, each carrying a unique risk of local recurrence and metastatic potential. In primary disease, surgery remains the mainstay of treatment and is the best opportunity for cure. In recurrent disease, treatment algorithms are less well defined. Surgery, radiation, systemic therapy, and in select cases, observation can be considered for management of recurrent disease. Histologic type drives a significant portion of clinical decision-making but incorporating all relevant clinicopathological data is important. To guide selection and timing of treatment, patients should undergo risk stratification. Nomograms and risk calculators are available to facilitate this. Experience and clinical judgement remain paramount. In the future, deeper molecular and radiologic characterization may further optimize decision-making in these challenging cases.
SN  - 1527-2729
SN  - 1534-6277
ER  -